Majid Hafezparast

Prof. Dr. Majid Hafezparast

Neuroscience, University of Sussex, Brighton, Brighton and Hove, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Nature Genetics
Verified
Journal Article
Closed access
JBJon A. Beck
Jon A. Beck
SLSarah Lloyd
Sarah Lloyd
MHMajid Hafezparast
Majid Hafezparast
MLMoyha Lennon-Pierce
Moyha Lennon-Pierce
JEJanan T. Eppig
Janan T. Eppig
EFElizabeth M.C. Fisher
Elizabeth M.C. Fisher

2 May 2003 in Science
Verified
Journal Article
Closed access
PDF file
MHMajid Hafezparast
Majid Hafezparast
RKRainer Klocke
Rainer Klocke
Christiana RuhrbergChristiana Ruhrberg
Christiana Ruhrberg
AMAndreas Marquardt
Andreas Marquardt
AAAzlina Ahmad-Annuar
Azlina Ahmad-Annuar
EFElizabeth M. C. Fisher
Elizabeth M. C. Fisher
Degenerative disorders of motor neurons include a range of progressive fatal diseases such as amyotrophic lateral sclerosis (ALS), spinal-bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). Although the causative genetic alterations are known for some cases, the molecular basis of many SMA and SBMA-like syndromes and most ALS cases is unknown. Here we show that missense point mutations in the cytoplasmic dynein heavy chain result in progressive motor neuron degeneration in heterozygous mice, and in homozygotes this is accompanied by the formation of Lewy-like inclusion bodies, thus resembling key features of human pathology. These mutations exclusively perturb neuron-specific functions of dynein.

1 September 2017 in Neurobiology of Disease
Verified
Journal Article
Open access
KVKurt J. De Vos
Kurt J. De Vos
MHMajid Hafezparast
Majid Hafezparast
Intracellular trafficking of cargoes is an essential process to maintain the structure and function of all mammalian cell types, but especially of neurons because of their extreme axon/dendrite polarisation. Axonal transport mediates the movement of cargoes such as proteins, mRNA, lipids, membrane-bound vesicles and organelles that are mostly synthesised in the cell body and in doing so is responsible for their correct spatiotemporal distribution in the axon, for example at specialised sites such as nodes of Ranvier and synaptic terminals. In addition, axonal transport maintains the essential long-distance communication between the cell body and synaptic terminals that allows neurons to react to their surroundings via trafficking of for example signalling endosomes. Axonal transport defects are a common observation in a variety of neurodegenerative diseases, and mutations in components of the axonal transport machinery have unequivocally shown that impaired axonal transport can cause neurodegeneration (reviewed in El-Kadi et al., 2007, De Vos et al., 2008; Millecamps and Julien, 2013). Here we review our current understanding of axonal transport defects and the role they play in motor neuron diseases (MNDs) with a specific focus on the most common form of MND, amyotrophic lateral sclerosis (ALS).

23 May 2005 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
DKDairin Kieran
Dairin Kieran
MHMajid Hafezparast
Majid Hafezparast
SBStephanie Bohnert
Stephanie Bohnert
JDJames R.T. Dick
James R.T. Dick
JMJoanne Martin
Joanne Martin
LGLinda Greensmith
Linda Greensmith
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition characterized by motoneuron degeneration and muscle paralysis. Although the precise pathogenesis of ALS remains unclear, mutations in Cu/Zn superoxide dismutase (SOD1) account for ∼20–25% of familial ALS cases, and transgenic mice overexpressing human mutant SOD1 develop an ALS-like phenotype. Evidence suggests that defects in axonal transport play an important role in neurodegeneration. In Legs at odd angles (Loa) mice, mutations in the motor protein dynein are associated with axonal transport defects and motoneuron degeneration. Here, we show that retrograde axonal transport defects are already present in motoneurons of SOD1G93A mice during embryonic development. Surprisingly, crossing SOD1G93A mice with Loa/+ mice delays disease progression and significantly increases life span in Loa/SOD1G93A mice. Moreover, there is a complete recovery in axonal transport deficits in motoneurons of these mice, which may be responsible for the amelioration of disease. We propose that impaired axonal transport is a prime cause of neuronal death in neurodegenerative disorders such as ALS.

18 September 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SRStuart L. Rulten
Stuart L. Rulten
ARAmy Rotheray
Amy Rotheray
RGRyan L. Green
Ryan L. Green
GGGabrielle Grundy
Gabrielle Grundy
DMDuncan A. Q. Moore
Duncan A. Q. Moore
KCKeith W Caldecott
Keith W Caldecott
Amyotrophic lateral sclerosis (ALS) is associated with progressive degeneration of motor neurons. Several of the genes associated with this disease encode proteins involved in RNA processing, including fused-in-sarcoma/translocated-in-sarcoma (FUS/TLS). FUS is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of proteins that bind thousands of pre-mRNAs and can regulate their splicing. Here, we have examined the possibility that FUS is also a component of the cellular response to DNA damage. We show that both GFP-tagged and endogenous FUS re-localize to sites of oxidative DNA damage induced by UVA laser, and that FUS recruitment is greatly reduced or ablated by an inhibitor of poly (ADP-ribose) polymerase activity. Consistent with this, we show that recombinant FUS binds directly to poly (ADP-ribose) in vitro, and that both GFP-tagged and endogenous FUS fail to accumulate at sites of UVA laser induced damage in cells lacking poly (ADP-ribose) polymerase-1. Finally, we show that GFP-FUSR521G, harbouring a mutation that is associated with ALS, exhibits reduced ability to accumulate at sites of UVA laser-induced DNA damage. Together, these data suggest that FUS is a component of the cellular response to DNA damage, and that defects in this response may contribute to ALS.

1 June 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EOEmily C. Oates
Emily C. Oates
ARAlexander M. Rossor
Alexander M. Rossor
MHMajid Hafezparast
Majid Hafezparast
MGMichael Gonzalez
Michael Gonzalez
FSFiorella Speziani
Fiorella Speziani
MRMary M. Reilly
Mary M. Reilly